DOCSLIB.ORG

Page Number/Name of CV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Page Number/Name of CV Danny Alon Ellenbogen, MD CV updated August 2017 1/ CURRICULUM VITAE Name: Danny Alon Ellenbogen, MD ID No.: 029436201 Faculty/Dept: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel/ Internal Medicine Hospital/Dept: Department of Internal Medicine B Rabin Medical Center – Beilinson Hospital Petach Tikva 4941492, Israel Email: [email protected] Date & Place of Birth: September 16, 1972, Israel ZAHAL (Israeli) Mar 1998 July 2002 RANK: MAJOR, ISRAEL AIR FORCE Military Service: (Enlisted) (Discharged) Marital Status: Married, 2 children A. EDUCATION PERIODS OF STUDIES 1990-1996 Hebrew University – Hadassah Medical School, Jerusalem, Israel Subject: Medicine MD degree Title of Doctoral Dissertation: Symptomatology in carriers of type 1 Gaucher disease Supervised by: Prof. Ari Zimran, MD MD License No.: 30090 Danny Alon Ellenbogen, MD CV updated August 2017 2/ C. ACADEMIC & PROFESSIONAL ACTIVITIES & ACHIEVEMENTS C1. Academic Experience: 2004, 2011 Tutor [Internal Medicine] to 4th and 6th year medical students, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2005, 2011 Tutor [Internal Medicine] to 3rd and 4th year medical students of the American program, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2005, 2011 Instructor, internal medicine residents, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2008-2010 Co-Moderator of the Travel Medicine Internet Site and Q&A Forum, Clalit Health Services and Tapuz Travel Health Forum 2009 Writing and instructing the Endocrinology Course, Meir Medical Center School of Nursing, Kfar Saba, Israel 2009 Lecturer [Infectious Diseases], Pre-clinical 4th year medical course 2011-2013 Team member of final internal medicine examination constructing committee [Head: Prof. Yair Levi], Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 2013 Lecturer [HIV], Tel Aviv University Internal Medicine Postgraduate Studies 10-11/2014 Team member of step B Internal Medicine Specialty Board Committee, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 10-12/2014, Team member of step B Infectious Diseases Specialty Board 10-12/2015, Committee, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 10-12/2016 Israel Ongoing Instructor [Internal Medicine], 4th and 6th year medical students, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Since 2014 Lecturer [Internal Medicine], Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Danny Alon Ellenbogen, MD CV updated August 2017 3/ C2. Professional Experience: 1997-1998 Internship, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel 2002-2006 Resident in Internal Medicine, Department of Internal Medicine B, Meir Medical Center, Kefar Saba, Israel [Prof. Josef Mekori] Title of Scientific Dissertation: Assessment of platelet adhesion and aggregation in fresh and stored blood products using the cone and platelet analyzer Supervised by: Martin Ellis, MD 2006-2008 Infectious Diseases Fellowship, Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel [Michal Chowers] 2008-2010 Senior Physician, Department of Medicine D, Meir Medical Center, Kfar Saba, Israel 2010-2011 Senior Physician, Infectious Diseases Unit and AIDS Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 2011-present Senior Physician, Department of Internal Medicine B, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel 2011-present Senior Physician, HIV Clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and Travel Medicine Clinic, Meir Medical Center, Kfar Saba, Israel Military Service: 1998-2000 Medical Officer, Military Engineering Regiment 200-2001 Clinic Commander, School of Military Engineering 2001-2002 Public Appeals Officer, Israeli Medical Corps 2001-2017 Reserve Medical Officer, Anti-Missile Unit, Israel Air Force Courses 2009 Good Clinical Practice Danny Alon Ellenbogen, MD CV updated August 2017 4/ C3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS Date Country Name of Meeting Role 19th European Congress of Clinical 2009 Helsinki, Finland Oral Presentation Microbiology & Infectious Diseases Israel Society for Parasitology, Protozoology & 2010 Ramat Gan, Israel Oral Presentation Tropical Diseases (SPPTD) Conference 2013 Brussels, Belgium 14th European AIDS Conference (EACS) Poster 2013 Jerusalem, Israel Israeli Heart Society (HIS) Conference Oral Presentation International Workshop on Antiviral Drug 2014 Berlin, Germany Poster Resistance C4. MEMBERSHIP IN PROFESSIONAL SOCIETIES Years (period) Name of Organization 2006-present Israel Society for Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases (ESCMD) Israel Society of Internal Medicine 2006-2013 Israel Society for Tropical Medicine 2007-present Israeli AIDS Society European AIDS Clinical Society (EAS) Danny Alon Ellenbogen, MD CV updated August 2017 5/ G. AWARDS May 2000 Received Chief Medical Corps Officer’s Excellence Award, Israel Independence Day Danny Alon Ellenbogen, MD CV updated August 2017 6/ SCIENTIFIC PUBLICATIONS B.1. ORIGINAL ARTICLES B.1. Articles Published 1. Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases among elderly travelers: a comparison of younger and older adults. J Travel Med. 2010;17(4):250-255. (MEDICINE, GENERAL & INTERNAL 58/154, Q2, IF 1.803, Cited 19) 2. Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Sprecher H, Lachish T, Wiener-Well Y, Alon D, Chowers M, Ciobotaro P, Bardenstein R, Paz A, Potasman I, Giladi M, Schechner V, Schwaber MJ, Klarfeld-Lidji S, Carmeli Y. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended- spectrum beta-lactamases. Antimicrob Agents Chemother. 2010;54(12):5099-5104. (PHARMACOLOGY & PHARMACY 36/256, Q1, IF 4.302, Cited 54) 3. Alon D, Abd-Elkadir F, Chowers M, Paitan Y. MRSA SCCmec epidemiology in Israel: Development and implementation of an MRSA SCCmec typing strategy. Eur J Clin Microbiol Infect Dis. 2011;30(11):1443-52. (INFECTIOUS DISEASES 38/84, Q2, IF 2.727, Cited 5) 4. Schechner V, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, Karplus R, Lazarovitch T, Braun E, Finkelstein R, Lachish T, Wiener-Well Y, Alon D, Chowers M, Bardenstein R, Zimhony O, Paz A, Potasman I, Giladi M, Schwaber MJ, Klarfeld-Lidji S, Hochman M, Marchaim D, Carmeli Y. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy. Diagn Microbiol Infect Dis. 2011;7(1):38-45. (MICROBIOLOGY 64/124, Q3, IF 2.401, Cited 13) 5. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sánchez-Castañón M, López-Hoyos M, Matucci-Cerinic M, Szücs G, Shapira Y, Szekanecz Z, Shoenfeld Y. Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev. 2011;10(8):490-494. (IMMUNOLOGY 11/150, Q1, IF 8.961, Cited 64) Danny Alon Ellenbogen, MD CV updated August 2017 7/ B.1. Articles Published 6. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;8(8):e72476. (MULTIDISCIPLINARY SCIENCES 15/64, Q1, IF 2.806, Cited 7) 7. Stein GY, Ben-Gal T, Kremer A, Bental T, Alon D, Korenfeld R, Yedidia I, Porter A, Abramson E, Sagie A, Fuchs S. Gender-related differences in hospitalized heart failure patients. Eur J Heart Fail. 2013;15(7):734-741. (CARDIAC & CARDIOVASCULAR SYSTEMS 12/126, Q1, IF 6.968, Cited 9) 8. Avidor B, Girshengorn S, Matus N, Talio H, Achsanov S, Zeldis I, Fratty IS, Katchman E, Brosh-Nissimov T, Hassin D, Alon D, Bentwich Z, Yust I, Amit S, Forer R, Vulih Shultsman I, Turner D. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J Clin Microbiol. 2013;51(3):880-886. (MICROBIOLOGY 33/124, Q2, IF 3.712, Cited 17) 9. Stein GY, Herscovici G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, Gevrielov-Yusim N, Iakobishvili Z, Fuchs S. Type-II myocardial infarction--patient characteristics, management and outcomes. PLoS One. 2014; Jan 2;9(1):e84285. (MULTIDISCIPLINARY SCIENCES 15/64, Q1, IF 2.806, Cited 22) 10. Obolski U*, Alon D*, Hadany L, Stein G. Resistance Profiles of CoNS Contaminating Blood Cultures Predict Pathogen Resistance and Patient Mortality. [*Equal contribution] J Antimicrob Chemother. 2014 Sep;69(9):2541-6. (PHARMACOLOGY & PHARMACY 23/256, Q1, IF 5.071, Cited 0) 11. Stein GY, Alon D, Korenfeld R, Fuchs S. Clinical implications of high-sensitivity cardiac troponin measurements in hospitalized medical patients. PLoS One. 2015 Jan 30;10(1):e0117162. (MULTIDISCIPLINARY SCIENCES 15/64, Q1, IF 2.806, Cited 2) 12. Oz N, Alon D, Chezar-Azerrad C, Cooper L, Levi Y, Fuchs S, Stein GY. Estimating Risk of Venous-Thromboembolic Events in Hospitalized Medical Patients: Comparison between 2008 and 2012 Guidelines. Isr Med Assoc J. 2016 Jun;18(6):346-9. (MEDICINE, GENERAL & INTERNAL 98/154, Q3, IF 1.036, Cited 0) Danny Alon Ellenbogen, MD CV updated August 2017 8/ B.1. Articles Published 13. Alon D, Stein GY, Hadas-Golan V, Tau L, Brosh T, Turner D. Immunogenicity of Sci-B-Vac (a Third-Generation Hepatitis B Vaccine) in HIV- Positive Adults. Isr Med Assoc J. 2017 Mar;19(3):143-146. (MEDICINE, GENERAL & INTERNAL 98/154, Q3, IF 1.036, Cited 0) 14. Oz N, Alon D, Stein GY, Turner D. Adherence and Characteristics
Load more

Recommended publications
  • Executive Summary Describes Some of the Fruits of the Ongoing Partnerships That Ensued
    E XECUTIVE S UMMARY February 2013 PPC G OES I NTERNATIONAL : T he Israel Healthcare Quality Partnership The Jewish Healthcare Foundation’s (JHF) longstanding commitment to health IN THIS ISSUE care that is both high quality and high value care has spurred its search for promising local, national, and international models and partnerships. Among international models, the Israeli healthcare system stands out. Identifying Opportunities to Share Best Practices 1 Spending just 8% of its Gross Domestic Product on health care (half the U.S. rate), Israel’s hybrid public-private system has achieved population health Israel Partnership outcomes that surpass those of many other western countries. Timeline 2 Intrigued, JHF led a group of twenty-three community leaders on a mission to The Fruits of Partnership 4 Israel in March 2009 to learn more. The ten-day tour of diverse Israeli healthcare facilities and meetings with providers, payers, and policy makers PPC Training Goes made it clear that JHF and its Israeli partners had much to learn from one Viral 8 another. This issue of Executive Summary describes some of the fruits of the ongoing partnerships that ensued. Speaking Engagements: PRHI’s Israel Debut 11 IDENTIFYING OPPORTUNITIES TO SHARE BEST PRACTICES The goals of JHF’s first study mission to Israel in March-April 2009 were to gather and to share breakthrough ideas for healthcare and social service 650 Smithfield Street improvement, and to learn from and with Israeli leaders in healthcare quality, Centre City Tower Suite 2400 health information technology, and innovative delivery models. Pittsburgh, PA 15222 412-586-6700 A team of JHF and PRHI (Pittsburgh Regional Health Initiative, a JHF operating [email protected] www.prhi.org arm) and twenty-three colleagues from Pittsburgh, Denver, and Chicago (specialists in healthcare delivery, finance, policy, aging, special needs, and education), discovered a healthcare system that spent half that of the U.S., on a per capita basis, and still achieved superior population health outcomes.
    [Show full text]
  • Scientific Program
    www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ.
    [Show full text]
  • The Effect of a National Lockdown in Response to COVID-19 Pandemic on the Prevalence of Clinical Symptoms in the Population
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.27.20076000; this version posted December 28, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . The effect of a national lockdown in response to COVID-19 pandemic on the prevalence of clinical symptoms in the population *1,2 *1,2 *1,2 *1,2,3 *1,2 1,2 Ayya Keshet ,​ Amir Gavrieli ,​ Hagai Rossman ,​ Smadar Shilo ,​ Tomer Meir ,​ Tal Karady ,​ Amit 1,2 ​ 1,2 ​ 1,2 ​1,2 ​ 1,2 ​ 4 ​ 4 Lavon ,​ Dmitry Kolobkov ,​ Iris Kalka ,​ Saar Shoer ,​ Anastasia Godneva ,​ Ori Cohen, Adam Kariv ,​ Ori Hoch ,​ ​ 4 ​ 4 ​ ​5 5 ​ 2 6 ​ 4​ Mushon Zer-Aviv ,​ Noam Castel ,​ Anat Ekka Zohar ,​ Angela Irony ,​ Benjamin Geiger ,​ Yuval Dor ,​ Dorit Hizi ,​ 7 ​ 5, 8 ​ 1,2,☨ ​ ​ ​ ​ ​ Ran Balicer ,​ Varda Shalev ,​ Eran Segal ​ ​ ​ * Equal​ contribution 1 ​ Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot, Israel. 2 ​ Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. 3 ​ Pediatric Diabetes Unit, Ruth Rappaport Children’s Hospital, Rambam Healthcare Campus, Haifa, Israel. 4 The​ public knowledge workshop, 26 Saadia Gaon st. Tel Aviv 5 ​ Epidemiology and Database Research Unit, Maccabi Healthcare Services, Tel Aviv, Israel. 6 School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University, Jerusalem, Israel. 7 ​ Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel. 8 ​ School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
    [Show full text]
  • Israel Endocrine Society
    Israel Endocrine Society Israel Endocrine Society Conference Browse the program for the upcoming event By Session All Sessions By ID 4 By Day Tuesday By Author Aizic, A. - 31 Now Viewing: All Sessions Note: The presenter's name is in bold Registration Tuesday Morning Date: Tuesday, April 9, 2013 Time: 7:30 AM - 8:00 AM Location: Oral Presentations I: Diabetes, Obesity and Metabolism Date: Tuesday, April 9, 2013 Time: 8:00 AM - 10:00 AM Location: Bareket Hall Session Chair: Benjamin Glaser Session Chair: Hannah Kanety 8:00 AM - AMPK corrects ER morphology and function in stressed pancreatic beta-cells via regulation of the ER resident protein DRP1 (ID: 25) Jakob Wikstrom (Israel) Tal Israeli (Israel) Etty Bachar-Wikstrom (Israel) Yafa Ariav (Israel) Erol Cerasi (Israel) Gil Leibowitz (Israel) 8:15 AM - Paradox In Metabolic Homeostasis: AHNAK Knockout Mice Are Resistant To Diet-Induced Obesity And Yet They Display Reduced Insulin Sensitivity (ID: 47) Maya Ramdas (Israel) Chava Harel (Israel) Natalia Krits (Israel) http://www.xcdsystem.com/ies2013/Program/index.cfm[05/04/2013 11:15:55] Israel Endocrine Society Michal Armoni, Rambam Medical Center (Israel) Eddy Karnieli, Institute of Endocrinology, Metabolism and Diabetes (Israel) 8:30 AM - Neonatal Wolfram syndrome: novel De-novo dominant mutation presenting as an unusual clinical phenotype (ID: 52) Abdulsalam Abu-Libdeh, Hadassah Hebrew University Hospital (Israel) 8:45 AM - Importance of maintaining redox potential balance in the development of type 2 diabetes (ID: 61) Tovit Rosenzweig,
    [Show full text]
  • Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of
    Dear Colleagues, It is our pleasure to invite you to the Annual Meeting of the Israel Neurosurgical Society which will be held at the Galilion Hotel, Israel. Although the main focus of the meeting will be Brain Tumors, the organizers will be happy to consider interesting talks on related subjects. Confirmed speakers to date that will share their experiences and update us in the latest developments include: Prof. Volker A. Coenen Dept. of Stereotactic and Functional Neurosurgery, University of Freiberg; Neurosurgery Clinic, Freiberg, Germany Prof. Garth Rees Cosgrov Dept. of Neurological Surgery, Brigham and Women's Hospital, Boston, MA, USA Prof. Hans Henkes Neuroradiological Clinic, Katharinenhospital, Stuttgart, Germany Prof. Robert H. Rosenwasser Dept. of Neurological Surgery, Jefferson Hospital for Neuroscience, Philadelphia, PA, USA As in previous meetings, we hope that this event will provide the opportunity to reconnect and meet with colleagues and to strengthen professional and personal ties among our members. We hope that you will be able to join us. Sincerely, Prof. Yigal Shoshann Prof. Mony Benifla Dr. Racheli Grossman President Secretary Treasurer 1 TENTATIVE TIMETABLE Wednesday, May 13, 2020 Light Lunch Afternoon Sessions Dinner Evening Social Event Thursday, May 14, 2020 Morning Sessions Lunch Afternoon Sessions Dinner Evening Social Event Friday, May 15, 2020 Morning Sessions Afternoon Sessions End and Light Lunch Meeting Secretariat Target Conferences Ltd. PO Box 51227, Tel Aviv 6713818, Israel Tel: +972 3 5175150, Fax: +972 3 5175155 e-mail: [email protected] www.israelneurosurgery.com 2 SCIENTIFIC ADVISORY COMMITTEE ON FUNCTIONAL NEUROSURGERY AND EPILEPSY Zvi Israel - Lead Advisor Dept. of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem Roberto Spiegelmann Dept.
    [Show full text]
  • Scientific Program
    The 63th Annual Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery April 12-13 • 2016 • Tel Aviv, Israel SCIENTIFIC PROGRAM Paragon Israel (Dan Knassim) Paragon Tel/Fax:03-5767730/7 Israel (Dan Knassim) a Paragon Group Company [email protected] TUESDAY, APRIL 12, 2016 08:30-10:00 Interventional Cardiology I Hall A Chairs: Ariel Finkelstein, Ran Kornowski, Israel 08:30 Effect of Diameter of Drug-Eluting Stents Versus Bare-Metal Stents on Late Outcomes: a propensity score-matched analysis Amos Levi1,2, Tamir Bental1,2, Hana Veknin Assa1,2, Gabriel Greenberg1,2, Eli Lev1,2, Ran Kornowski1,2, Abid Assali1,2 1Cardiology, Rabin Medical Center, Israel 2Sackler Faculty of Medicine, Tel Aviv University, Israel 08:41 Percutaneous Valve-in-Valve Implantation for the Treatment of Aortic, Mitral and Tricuspid Structural Bioprosthetic Valve Degeneration Uri Landes1, Abid Assali1, Ram Sharoni1,2, Hanna Vaknin-Assa1, Katia Orvin1, Amos Levi1, Yaron Shapira1, Shmuel Schwartzenberg1, Ashraf Hamdan1, Tamir Bental1, Alexander Sagie1, Ran Kornowski1 1Department of Cardiology, Rabin Medical Center, Tel Aviv, Israel 2Department of Cardiac Surgery, Rabin Medical Center, Tel Aviv, Israel 08:52 Temporal Trends in Transcatheter Aortic Valve Implantation in Israel 2008-2014: Patient Characteristics, Procedural Issues and Clinical Outcome Uri Landes1, Alon Barsheshet1, Abid Assali1, Hanna Vaknin-Assa1, Israel Barbash3, Victor Guetta3, Amit Segev3, Ariel Finkelstein2, Amir Halkin2, Jeremy Ben-Shoshan2,
    [Show full text]
  • Israel Network Integrates Clinical Data for 8 Million Patients
    Israel network Client Profile Clalit Health Services integrates clinical data Tel Aviv, Israel for 8 million patients OVERVIEW Case Study • One of the world’s largest HMOs/IDNs • 4.2 million clients • 5,500 beds • 14 hospitals, 1,300 clinics, 420 pharmacies • 40,000 employees, including 9,000 physicians and 11,500 nurses • 60 million primary care encounters • 2.2 million ambulatory care visits • +1 million emergency room visits • 350,000 admissions • 130,000 surgical procedures ALLSCRIPTS SOLUTIONS • Allscripts dbMotion™ • Allscripts dbMotion™ Agent +25,000 Users The desire to aggregate patient information from disparate sources, do it quickly and present it in a way that made sense to caregivers gave rise to what is now called the Ofek Network, powered by the Allscripts dbMotion™ Solution, across Clalit Health Services. It connects multiple health systems that serve +2,000,000 Israel’s 8.3 million residents. Patient records viewed per month The technology compiles a view-only patient record in less than 10 seconds, freeing physicians to spend more quality time with patients, saving money on unnecessary tests and procedures, as well as reducing the incidence of complication. Because the solution sits above existing records systems to pull information based on search parameters, no +15,000,000 Pages changes to those legacy technologies are required for implementation. viewed per month Clalit Health Services has achieved significant savings across its organization by reducing unnecessary labs and imaging studies. It also achieves better patient outcomes that occur when a provider can view the pertinent portions of a patient’s <10 Seconds Avg. records in a dashboard format, with the ability to drill down into information.
    [Show full text]
  • Antibiotic Treatment for Invasive Listeriosis and Patient
    Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality.
    [Show full text]
  • Supplementary Figures for “Evidence for Increased Breakthrough Rates of SARS-Cov-2 Variants of Concern in Bnt162b2 Mrna Vaccinated Individuals“
    Supplementary figures for “Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals“ Talia Kustin*1,2, Noam Harel*1,2, Uriah Finkel3, Shay Perchik3, Sheri Harari1,2, Maayan Tahor1, Itamar Caspi1, Rachel Levy1, Michael Leschinsky3, Shifra Ken Dror4, Galit Bergerzon4, Hala Gadban4, Faten Gadban4, Eti Eliassian5, Orit Shimron5, Loulou Saleh6, Haim Ben-Zvi6, Doron Amichay7,8, Anat Ben-Dor7, Dana Sagas9, Merav Strauss9, Yonat Shemer Avni10,11, Amit Huppert12,13, Eldad Kepten3, Ran D. Balicer3, Doron Nezer14*, Shay Ben-Shachar3,13*†, Adi Stern1,2† * These authors contributed equally † Corresponding authors: [email protected], [email protected] 1. The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 2. Edmond J. Safra Center for Bioinformatics, Tel Aviv University, Tel Aviv, Israel 3. Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel 4. Clalit Health Services, Central Laboratories, Haifa and Western Galilee, Israel 5. Progenin Laboratories, Jerusalem District, Clalit Health Services, Israel 6. Microbiology lab, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel 7. Central Laboratory, Clalit Health Services, Tel Aviv, Israel 8. Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University, Beersheba, Israel 9. Microbiology Laboratory, Emek Medical Center, Afula, Israel 10. Laboratory of Clinical Virology, Soroka University Medical Center. Beersheba, Israel 11. Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheba, Israel 12. The Bio-statistical and Bio-mathematical Unit, The Gertner Institute for Epidemiology and Health Policy Research, Chaim Sheba Medical Center, Tel Hashomer, Israel 13.
    [Show full text]
  • APF Newsletter, Winter 2006 – 2007
    Winter 2006-2007 APF A Newsletter of the From The President AmericanEmergency Physicians andFellowship Disaster Preparednessfor Medicine in Israel Course News in Israel From The President Israel in Crisis Mission August 2006 would like to share with our members and donors the important by Dr. Dan Moskowitz I APF activities of the past 6 months. his past August, I had the privilege of being invited to par- 1. APF ISRAEL CRISIS FUND REPORT After placing on our T ticipate in an Emergency APF Mission to Israel with APF website and sending a special crisis appeal from Dr. Danny Laor, Board members Drs. Mike Frogel, Paul Liebman and Charles the Deputy Minister for Emergency Preparedness, on the critical Kurtzer. Dr. Boaz Tadmor organized an incredible, whirlwind needs of the Northern hospitals, it was very gratifying indeed that over $100,000 tour for us, only two days after the cessation of hostilities in was received for our Crisis Fund. All of this will be distributed to hospitals such as Israel. We were provided with a unique glimpse of the Israeli Sieff Hospital in Safed, Poriya in Tiberias, Western Galilee Medical Center in Nahariya, and Rambam Medical Center in Haifa, with the hospital CEO’s given the healthcare system under stress, including face-to-face meet- discretion as to how best to utilize these funds to help their hospital in light of the ings with top healthcare officials, as well as visits to the trau- recent crisis. matized hospitals in northern Israel. Perhaps most importantly, we visited 2. MISSION TO ISRAEL Three APF Board members, Drs.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2020-040210 on 8 February 2021. Downloaded from PipEracillin Tazobactam versus mERoPENem for treatment of bloodstream infections caused by cephalosporin-resistant Enterobacteriaceae - a non-inferiority randomized controlled trial (PeterPen) ForJournal: peerBMJ Open review only Manuscript ID bmjopen-2020-040210 Article Type: Protocol Date Submitted
    [Show full text]
  • ISPOR Israel Chapter Annual Report 2010
    ISPOR Israel Chapter Annual Report 2010 TO: Board of Directors International Society for Pharmacoeconomics and Outcomes Research 3100 Princeton Pike, Suite 3E Lawrenceville, NJ 08648 USA PREPARED BY: Shmuel Klang, PhD Department of Pharmacy and Pharmacology Clalit Health Services Tel-Aviv, Israel Tel: 972-3- -3326 Fax: 972-3-692-3322 E-mail:[email protected] Background: The Israel Local Chapter was accepted in September 2007. The Chapter has 62 members. The current Executive Board of the Israel Local Chapter is: President Shmuel Klang, PhD (2010-2011) Clalit Health Services Headquarters Tel-Aviv, Israel Vice President Nicky Lieberman, MD (2010-2011) Clalit Health Services Headquarters Tel-Aviv, Israel Secretary Noa Triki, PhD Maccabi Healthcare Services Headquarters Tel Aviv, Israel Treasurer Barak Palatchi, BA Director Dan Greenberg, PhD Department of Health Systems Management Ben-Gurion University of the Negev Beer-Sheva, Israel Israel Chapter Annual Report 20 Director Mordi Rabinovich, MBA (PhD candidate) Strategic Consulting Services Market Access & Reimbursement Nes-Ziona, Israel Director Erez Shem-Tov, MBA Abbott Israel Tel-Aviv, Israel For more information on the Israel Chapter, please visit the ISPOR Regional Chapter website http://www.ispor.org/local_chapters/Israel/index.asp. Enclosure: ISPOR Israel Chapter Annual Report 2010 2 Israel Chapter Annual Report 20 ISPOR Israel Chapter Annual Report 2010 Activities/ Summary Accomplishments Scientific / 1 day seminar was held in the Lin regional clinic of Clalit Health Educational Services in Haifa. During the seminar, ISPOR-Israel members Activities (Shmuel Klang, Oren Shavit, Moshe Leshno, Mordi Rabinovich, and Dan Greenberg) presented various topics on methods for economic evaluations and budget impact analysis.
    [Show full text]